Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from CDER

‘The FDA is a complete mess’: Trump makes fate of agency chief unclear as public trust plummets

Food and Drug Administration commissioner’s decisions have hurt staff morale and put his job in crosshairs

The Guardian - US

Turmoil and tensions at FDA after dramatic exit of top drug regulator

Scramble to find replacement for George Tidmarsh shines light on dysfunction at US regulatory agency

The Guardian - US

Can’t pay and they really do take it away: what happens when the bailiffs come knocking

First, Sharron’s car was impounded. But what followed shows how the poor are punished for their poverty

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Man forced to pay bailiffs £500 fine after council misreads his number plate

Steven Ward, 41, says he was woken up by bailiffs from enforcement firm CDER Group threatening to take his and his girlfriend’s cars off their driveway

Daily Mirror

Tyne Tunnel debt recovery firms under fire for 'threatening and misleading' language in letters

The trade association for debt collection, the CSA, have criticised Marston Recovery and Court Enforcement Services about the wording of their debt enforcement letters

Chronicle Live

Here's How Citi Views Amylyx Pharma

Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review. Availability in Canada and using ALSFRS-R data as the primary basis…

Benzinga

What's The FDA's Regulatory Impact On The Cannabis Industry? Find Out In This Webinar

What's the Food and Drug Administration's impact on the cannabis industry?

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Ardelyx Shares Are Rising

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company’s second level of appeal of the Complete Response Letter for XPHOZAH.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Food and Drug Administration

Birmingham City Council

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.